Scientists will work in the Boehringer Ingelheim-Tsinghua University Joint Research Center for Immuno-Infection to harness the mechanisms of immune modulation to combat infectious diseases.
The collaboration brings together the leading expertise of Tsinghua University in infectious disease research and immunology with Boehringer Ingelheim's experience in the development of novel therapies for patients suffering from diseases with high unmet medical need and its comprehensive research and development programs in cancer immunology and immune modulation.
Infectious diseases such as lower respiratory tract infections (e.g. bacterial/viral pneumonia) and tuberculosis are amongst the leading causes of mortality and morbidity worldwide.
In China, chronic hepatitis B and tuberculosis are of high prevalence and associated with high mortality. Although pathogen-directed treatments and vaccinations have greatly reduced the impact of infectious diseases in past decades, they continue to be a major challenge for health.
Increasing levels of resistance threaten the effectiveness of many anti-microbial drugs. No new antibiotic classes were developed during the past three decades and many treatments fail to achieve cure, resulting in large numbers of patients at risk due to long-term persistent infections.
Similar to cancer, many pathogens may inhibit or modulate their host's immune system and thus circumvent immune defense. Immune system activating therapies, which have brought a major therapeutic breakthrough in cancer may open similar transformative opportunities for infectious disease treatment.
This collaboration is an initiative of Boehringer Ingelheim's Research Beyond Borders and Cancer Immunology and Immune Modulation Research Departments.
Immuno-infection is a new focus area for Boehringer Ingelheim's RBB department, which also focuses on gene therapy, regenerative medicine and the role of the microbiome in human health and disease.
With the new collaboration, Boehringer Ingelheim further expands its activities in the growing biomedical innovation hot spot of China. By combining a focus on cutting-edge science with a long-term view, the company aspires to develop the next generation of medical breakthroughs to improve the lives of patients suffering from diseases with high unmet medical needs.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial